Skip to content

Inspection Record

Nelson Laboratories, LLC — FDA 483 Findings

US FDAInspected 2025-07-30Published 2026-10-26 11 findingsContamination controlMaterial and supplier controlOther quality systemTraining and personnelDeviation, CAPA, and investigationProcess validationEquipment and facilityLaboratory and QC controls

Inspectors Emily B Camire · Laurissa S FlowersThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing and that does not increase the risk of introduction, transmission, or spread of communicable disease.

2Material and supplier control

Each lot of components was not appropriately identified as to its status in terms of being quarantined, approved or rejected.

3Other quality system

In-process inspections, tests, or other verification activities and approvals were not documented.

4Training and personnel

The quality program has not ensured the proper training and education of personnel involved in core GTP activities.

5Deviation, CAPA, and investigation

Deviations from written production and process control procedures are not justified.

6Process validation

Specified requirements for in-process controls were not met.

7Other quality system

The quality program has not established and maintained appropriate monitoring systems.

8Other quality system

Records were not detailed as necessary to provide a complete history of work performed.

9Equipment and facility

Environmental conditions existed in which contamination or cross contamination of HCT/Ps or equipment could occur, and environmental conditions were not adequately controlled.

10Other quality system

Procedures were not designed to prevent circumstances that increase the risk of communicable disease introduction, transmission and spread through the use of HCT/Ps.

11Laboratory and QC controls

Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Nelson Laboratories, LLC company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.